-

Scott+Scott Attorneys at Law LLP Investigates Clover Health Investments, Corp.’s Directors and Officers for Breach of Fiduciary Duties – CLOV, IPOC

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Clover Health Investments, Corp. (“Clover Health”) (NASDAQ: CLOV); f/k/a Social Capital Hedosophia Holdings Corp. III (“SCH III”) (NYSE: IPOC) breached their fiduciary duties to SCH III and its shareholders. If you were an SCH III shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or jpettigrew@scott-scott.com.

Scott+Scott is investigating whether SCH III’s board of directors or senior management failed to manage SCH III in an acceptable manner, in breach of their fiduciary duties to SCH III shareholders, and whether SCH III’s shareholders suffered damages as a result.

On January 7, 2021, SCH III closed a merger transaction, with Clover Health continuing as the successor entity. On February 4, 2021, Hindenburg Research issued a report claiming that Clover Health was misleadingly hiding governmental investigations from the public.

What You Can Do

If you were a, SCH III shareholder, you may have legal claims against SCH III’s directors and officers. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at 844-818-6982 or jpettigrew@scott-scott.com.

About Scott+Scott

Scott+Scott has significant experience in prosecuting major securities, antitrust, and consumer rights actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Amsterdam, Connecticut, California, Virginia, and Ohio.

Attorney Advertising

Scott+Scott Attorneys at Law LLP

NASDAQ:CLOV

Release Summary
Scott+Scott Attorneys at Law LLP Investigates Clover Health Investments, Corp.’s Directors and Officers for Breach of Fiduciary Duties – CLOV, IPOC
Release Versions

More News From Scott+Scott Attorneys at Law LLP

UBIQUITI INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Ubiquiti Inc.’s Directors and Officers for Breach of Fiduciary Duties – UI

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the leadership of Ubiquiti Inc. (“Ubiquiti”) (NYSE: UI) breached their fiduciary duties to Ubiquiti and its shareholders. CLICK HERE TO LEARN MORE Scott+Scott is investigating whether members of Ubiquiti’s board of directors or senior management failed to manage Ubiquiti in an acceptable manner, in breach of their fiduciary duties...

ELI LILLY AND COMPANY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company’s Directors and Officers for Breach of Fiduciary Duties – LLY

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the leadership of Eli Lilly and Company (“Eli Lilly”) (NYSE: LLY) breached their fiduciary duties to Eli Lilly and its shareholders. CLICK HERE TO LEARN MORE Scott+Scott is investigating whether members of Eli Lilly’s board of directors or senior management failed to manage Eli Lilly in an acceptable manner, in breach of their fid...

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation Into Corcept Therapeutics Incorporated (NASDAQ: CORT)

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws. CLICK HERE TO RECEIVE ADDITIONAL INFORMATION ABOUT THIS POTENTIAL CLASS ACTION Corcept...
Back to Newsroom